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complications. Orlistat, a drug for achieving and main-
taining weight loss, reduces cardiovascular risk factors in
randomized clinical trials. The objectives of this study
were to estimate the resulting long-term clinical conse-
quences and cost-effectiveness of treating obese type 2 di-
abetic patients with orlistat.
METHODS: A Markov model was developed to predict,
over a 10-year period, the complication rates and mortal-
ity with and without a two-year orlistat treatment, as-
suming a five-year weight catch-up period after treatment
according to epidemiological evidence. A stepwise ap-
proach was used to apply published clinical data into pre-
diction of long-term outcome. As a first step, the impact
of orlistat on HbA1c, blood pressure and cholesterol was
obtained. In a second step, the impact of decreasing these
risk factors on mortality and micro- and macrovascular
complications was obtained. Four subgroups, defined by
the presence of arterial hypertension and/or hypercholes-
terolemia, were studied.
RESULTS: Cost-effectiveness varies between 3,462 Euro/
life year gained (LYG) for obese diabetic patients with hy-
pertension and hypercholesterolemia, and 19,986 Euro/
LYG for obese diabetic patients without other risk fac-
tors. Sensitivity analyses on all relevant variables indicate
that these results are very robust.
CONCLUSIONS: Our results suggest that orlistat is cost-
effective in the management of obese type 2 diabetic pa-
tients, especially in those with concomitant hypercholes-
terolemia and/or hypertension.
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OBJECTIVE: Despite the existence of effective therapy,
millions of Europeans have blood pressure (BP) above in-
ternationally agreed targets for control of cardiovascular
risk. There is particular resistance to aggressive manage-
ment of the elderly. We estimated the acute health-care
costs resulting from failure to achieve BP targets in older
adults in France, Germany, Italy, Sweden and the UK.
METHODS: We constructed a burden of disease model
to estimate the costs of uncontrolled hypertension in this
group. Prevalence of uncontrolled hypertension was
taken from the MONICA study and published surveys.
The relationships between three cardiovascular (CV)
events (symptomatic acute myocardial infarction (AMI),
congestive heart failure (CHF) and stroke) and BP were
estimated from a large prospective study (the HOT trial).
Costs came from government sources and published stud-
ies. We estimated the acute medical costs of these events
at current prevalence of uncontrolled hypertension and
expected number of events and cost if BP were treated to
target levels. Stochastic simulation was used to construct
confidence intervals.
RESULTS: Among adults older than 65 years in the five
countries, an estimated 15.2m have BP above 160/95
mmHg and a further 12.9m have BP in the range 140/90–
160/95 mmHg. The model estimated that 505,000 CV
events (AMI–91,000; CHF–190,000, stroke–224,000)
occur each year in those older than 65 in these countries,
resulting in annual acute hospital costs of Euro2.3Bn
(95% CI Euro2.04–2.53Bn). One hundred twenty eight
thousand of these events (AMI–9,000; CHF–55,000,
stroke–64,000) could be avoided if BP targets were met.
The annual cost of these avoidable events was estimated
to be Euro560m (95% CI Euro300–783m), representing
24.2% of the acute medical cost of these CV events in
this population.
CONCLUSION: Failing to implement existing guidelines
for BP management in the elderly contributes substan-
tially to the total human and economic burden of CV dis-
ease.
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OBJECTIVE: The reliable and valid capture of patient-
reported outcomes (PROs) are becoming increasingly im-
portant endpoints for the pharmaceutical industry. PROs
are data reported by the patient, and can include health-
related quality of life, functional status, symptoms, pain,
bother, satisfaction, work loss, reduced productivity, and
the use of medical resources. These data, when included
in studies, have traditionally been collected using paper-
based methods. Technological advances in electronic
data capture, such as handheld computers, internet-based
solutions, and interactive voice-response systems, facili-
tate collecting PROs and are important new tools for
clinical and outcomes researchers. Our objective was to
examine compliance rates between a handheld computer
diary system and a paper-based diary.
METHODS: Eighty pain patients were randomly as-
signed to complete a three-week, diary-monitoring proto-
col using either a compliance-enhanced electronic diary
system or a paper diary. The paper diary was covertly in-
strumented to allow for objective determination of when
the diary was opened or closed.
RESULTS: Participants submitted diary cards corre-
sponding to 89% of assigned assessment times (15
min). However, the electronic record indicated that ac-
tual compliance with the paper diary was only 11%, indi-
cating a high level of faked compliance. On 32% of all
study days the paper diary was not opened, yet reported
